Israel Acquisitions (ISRL) pushes Gadfin merger termination date to May 31, 2026
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Israel Acquisitions Corp disclosed that it entered into a fifth amendment to its Business Combination Agreement with Gadfin Ltd. and Gadfin Regev Holdings Ltd. on May 15, 2026. The amendment extends the agreement’s termination date to May 31, 2026, while leaving all other termination rights unchanged.
The filing also lists the prior Business Combination Agreement dated January 26, 2025 and four earlier amendments from July 2, 2025, December 31, 2025, March 13, 2026, and April 15, 2026, highlighting an ongoing effort to complete the planned transaction with Gadfin.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 1.01, 9.01
2 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
New termination date: May 31, 2026
Fifth amendment date: May 15, 2026
Warrant exercise price: $11.50 per share
+1 more
4 metrics
New termination date
May 31, 2026
Revised in Fifth Business Combination Agreement Amendment
Fifth amendment date
May 15, 2026
Date Amendment No. 5 to BCA was signed
Warrant exercise price
$11.50 per share
Each redeemable warrant exercisable for one Class A ordinary share
Original BCA date
January 26, 2025
Initial Business Combination Agreement with Gadfin Ltd.
Key Terms
Business Combination Agreement, Material Definitive Agreement, redeemable warrants, emerging growth company, +1 more
5 terms
Business Combination Agreement financial
"entered into a business combination agreement on January 26, 2025"
A business combination agreement is a detailed contract that lays out the terms for two companies to join together—covering price, how ownership will be split, the steps needed to close the deal, and what each side promises to do or avoid before closing. For investors it matters because the agreement determines potential changes in value, control, timing, and risk exposure—think of it like the playbook for a merger that shows who wins, who pays, and what could still derail the plan.
Material Definitive Agreement regulatory
"Item 1.01. Entry into a Material Definitive Agreement."
A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.
redeemable warrants financial
"Redeemable warrants, each whole warrant exercisable for one Class A ordinary share"
A redeemable warrant is a tradable right that lets its holder buy a company’s shares at a fixed price before a set date, but the issuer has the contract power to cancel (redeem) the warrant early under agreed terms. For investors this matters because early redemption can force decision-making, change the timing of when new shares might be created, and affect potential gains or dilution—much like a store coupon that the issuer can cancel by paying you off instead of letting you use it.
emerging growth company regulatory
"Emerging growth company x"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
exercise price financial
"each at an exercise price of $11.50 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What did Israel Acquisitions Corp (ISRL) announce about its Gadfin transaction?
Israel Acquisitions Corp reported a fifth amendment to its Business Combination Agreement with Gadfin Ltd. signed on May 15, 2026. The amendment mainly extends the agreement’s termination date to May 31, 2026, while keeping all other termination rights in place.
How did the fifth amendment change the Gadfin deal for Israel Acquisitions Corp (ISRL)?
The fifth amendment revises Section 7.1(d) of the Business Combination Agreement to extend the termination date to May 31, 2026. All other termination rights under the existing agreement remain, indicating the parties are preserving flexibility while continuing to pursue the combination.
Who are the parties to Israel Acquisitions Corp’s Business Combination Agreement?
The Business Combination Agreement involves Israel Acquisitions Corp, Gadfin Ltd., and Gadfin Regev Holdings Ltd. The original agreement was signed on January 26, 2025 and has since been amended five times, most recently on May 15, 2026, to adjust key terms such as termination timing.
What securities of Israel Acquisitions Corp (ISRL) are trading and under which symbols?
Israel Acquisitions Corp’s units, Class A ordinary shares, and redeemable warrants trade on the OTC Markets. The units trade under “ISLUF,” the Class A ordinary shares under “ISRLF,” and the redeemable warrants under “ISLWF,” each representing different components of the SPAC’s capital structure.
What are the terms of Israel Acquisitions Corp’s redeemable warrants?
Each redeemable warrant is exercisable for one Class A ordinary share at an exercise price of $11.50 per share. These warrants trade under the symbol “ISLWF” and provide holders with the right to purchase ordinary shares at that fixed price if they choose to exercise.